S
Shenzhen Hongxin Biotechnology
Biotech & Life Sciences · Ningbo, China · Founded 2021
RNA drug development and nucleic acid delivery MoreLess
Shenzhen Hongxin Biotechnology Co., Ltd., also known as MagicRNA, is a clinical-stage biotechnology company founded in 2021 and headquartered in Shenzhen, China. The company focuses on developing RNA drugs and advancing nucleic acid delivery technologies to treat a range of diseases, including cancer, infectious diseases, and autoimmune disorders like Systemic Lupus Erythematosus (SLE).
MagicRNA has developed three core technology platforms: an mRNA sequence design platform, an mRNA synthesis platform, and a lipid nanoparticle (LNP) delivery platform. A key component of their technology is the proprietary Engineered Cell-targeted LNP (EnC-LNP) platform, which enables the precise delivery of mRNA to specific cells beyond the liver, overcoming a significant limitation of conventional LNP systems. The company has created an extensive ionizable amino lipid library to support this platform.
The firm's business model includes providing custom mRNA synthesis and LNP encapsulation services to other biotech and pharmaceutical clients. MagicRNA's pipeline features infectious disease mRNA vaccines, mRNA tumor vaccines, and protein replacement therapies. Their lead candidate, HN2301, is an in vivo CAR T-cell therapy for treating refractory SLE. In September 2025, the company published first-in-human clinical data for HN2301 in The New England Journal of Medicine, demonstrating its ability to generate functional CAR T-cells directly within a patient's body.
Since its inception, MagicRNA has secured significant funding, including a Series A round in December 2025 with investors such as MPC, Tencent Investment, and IDG Capital. The company has established research and development labs in Shenzhen, with a team where over 80% hold a master's degree or higher, and collaborates with institutions like Sun Yat-sen University Affiliated Hospital.
Keywords: RNA therapeutics, mRNA vaccines, lipid nanoparticles, LNP delivery, nucleic acid drugs, in vivo CAR-T, cancer therapy, autoimmune diseases, gene therapy, drug delivery systems, biopharmaceuticals, oncology, molecular science, Shenzhen, clinical-stage biotechnology, Systemic Lupus Erythematosus, protein replacement therapy, custom mRNA synthesis, EnC-LNP platform
Company overview
Shenzhen Hongxin Biotechnology company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Ningbo, China
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 21.7
Valuation & funding
Shenzhen Hongxin Biotechnology funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Aug 2026 | $28M | $110M | Sino Biopharmaceutical · Ace Global Business Acquisition Limited · Nanling Venture Capital · BOC Financial Assets Investment | ↗ |
| EARLY VC✓Equity / VC | Dec 2025 | $352K | $14M | Undisclosed | ↗ |
| SEED✓Equity / VC | Jan 2024 | $2.8M | $11M | Hongtao Capital · Deep Angel Direct Investment Fund · Goldport Capital · Synthetic Capital | ↗ |
Growth signals
Shenzhen Hongxin Biotechnology website traffic
Latest recorded traffic for Shenzhen Hongxin Biotechnology is 2.5K monthly website visits, up 38.9% over the last three months.
Comparisons
Shenzhen Hongxin Biotechnology compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Changsen PharmaceuticalInnovative drug development for viral and autoimmune diseases |
China | Operational | 2 | — | — |
 Neologics BioscienceClinical-stage immuno-modulating antibody therapeutics for cancer |
Changzhou, China | Operational | |||
 Hangzhou Bangshun PharmaceuticalInnovative drugs for oncology, autoimmune, and inflammatory diseases |
Hangzhou, China | Operational | |||
 one-carbon TherapeuticsFocuses on developing treatments for cancer, inflammation, and autoimmune diseases |
Stockholms kommun, Sweden | Operational | |||
 Legacy HealthcareBiopharma developing innovative botanical drugs in supportive oncology care and dermatology |
Epalinges, Switzerland | Operational | |||
 Celsius TherapeuticsSingle-cell RNA sequencing and genomic analysis |
Cambridge, United States | Acquired | |||
 SilenseedRNAi-based cancer drugs with proprietary delivery system |
Modi'in-Maccabim-Re'ut, Israel | Operational | |||
 Acerta PharmaClinical research on cancer and autoimmune diseases |
Oss, Netherlands | Acquired |
Talent graph
Shenzhen Hongxin Biotechnology's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Shenzhen Hongxin Biotechnology has talent and traffic
In the news
Latest news about Shenzhen Hongxin Biotechnology
Recent press, funding announcements, and product moves mentioning Shenzhen Hongxin Biotechnology — open to read from the original sources.
Market sentiment
What the market is saying about Shenzhen Hongxin Biotechnology
An AI-synthesized read of the highest-engagement posts about Shenzhen Hongxin Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shenzhen Hongxin Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.